deltatrials
Active Not Recruiting PHASE1 NCT01660971

Gemcitabine Hydrochloride, Dasatinib, and Erlotinib Hydrochloride in Treating Patients With Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery

A Phase 1 Study of Gemcitabine, Dasatinib and Erlotinib in Patients With Advanced Pancreatic Carcinoma

Sponsor: National Cancer Institute (NCI)

Conditions Metastatic Pancreatic Adenocarcinoma Recurrent Pancreatic Carcinoma Stage III Pancreatic Cancer AJCC v6 and v7 Stage IV Pancreatic Cancer AJCC v6 and v7
Interventions Dasatinib Erlotinib Hydrochloride Gemcitabine Hydrochloride
Updated 34 times since 2017 Last updated: Mar 12, 2026 Started: Jul 30, 2012 Primary completion: Sep 6, 2017 Completion: Mar 19, 2026

This PHASE1 trial investigates Metastatic Pancreatic Adenocarcinoma and Recurrent Pancreatic Carcinoma and is currently ongoing. National Cancer Institute (NCI) leads this study, which shows 34 recorded versions since 2012 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Change History

34 versions recorded

  1. Mar 2026 — Present [monthly]

    Active Not Recruiting PHASE1

  2. Oct 2025 — Mar 2026 [monthly]

    Active Not Recruiting PHASE1

  3. Apr 2025 — Oct 2025 [monthly]

    Active Not Recruiting PHASE1

  4. Oct 2024 — Apr 2025 [monthly]

    Active Not Recruiting PHASE1

  5. Sep 2024 — Oct 2024 [monthly]

    Active Not Recruiting PHASE1

▶ Show 29 earlier versions

  1. Aug 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE1

  2. Jul 2024 — Aug 2024 [monthly]

    Active Not Recruiting PHASE1

  3. Apr 2024 — Jul 2024 [monthly]

    Active Not Recruiting PHASE1

  4. Nov 2023 — Apr 2024 [monthly]

    Active Not Recruiting PHASE1

  5. Oct 2023 — Nov 2023 [monthly]

    Active Not Recruiting PHASE1

  6. Sep 2023 — Oct 2023 [monthly]

    Active Not Recruiting PHASE1

  7. Feb 2023 — Sep 2023 [monthly]

    Active Not Recruiting PHASE1

  8. Jul 2022 — Feb 2023 [monthly]

    Active Not Recruiting PHASE1

  9. Jan 2022 — Jul 2022 [monthly]

    Active Not Recruiting PHASE1

  10. Sep 2021 — Jan 2022 [monthly]

    Active Not Recruiting PHASE1

  11. Jan 2021 — Sep 2021 [monthly]

    Active Not Recruiting PHASE1

  12. Jul 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE1

  13. Jun 2020 — Jul 2020 [monthly]

    Active Not Recruiting PHASE1

  14. May 2020 — Jun 2020 [monthly]

    Active Not Recruiting PHASE1

  15. Apr 2020 — May 2020 [monthly]

    Active Not Recruiting PHASE1

  16. Mar 2020 — Apr 2020 [monthly]

    Active Not Recruiting PHASE1

  17. Feb 2020 — Mar 2020 [monthly]

    Active Not Recruiting PHASE1

  18. Jan 2020 — Feb 2020 [monthly]

    Active Not Recruiting PHASE1

  19. Dec 2019 — Jan 2020 [monthly]

    Active Not Recruiting PHASE1

  20. Nov 2019 — Dec 2019 [monthly]

    Active Not Recruiting PHASE1

  21. Sep 2019 — Nov 2019 [monthly]

    Active Not Recruiting PHASE1

  22. Jul 2019 — Sep 2019 [monthly]

    Active Not Recruiting PHASE1

  23. Jun 2019 — Jul 2019 [monthly]

    Active Not Recruiting PHASE1

  24. Aug 2018 — Jun 2019 [monthly]

    Active Not Recruiting PHASE1

  25. Jun 2018 — Aug 2018 [monthly]

    Active Not Recruiting PHASE1

  26. Aug 2017 — Jun 2018 [monthly]

    Active Not Recruiting PHASE1

  27. Jun 2017 — Aug 2017 [monthly]

    Active Not Recruiting PHASE1

  28. Feb 2017 — Jun 2017 [monthly]

    Active Not Recruiting PHASE1

  29. Jan 2017 — Feb 2017 [monthly]

    Active Not Recruiting PHASE1

    First recorded

Jul 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • National Cancer Institute (NCI)
Data source: National Cancer Institute (NCI)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Nashville, United States